Skip Navigation



JAC Advance Access published online on November 1, 2006
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkl433
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
59/1/144    most recent
dkl433v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Zhanel, G. G.
Right arrow Articles by Hoban, D. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhanel, G. G.
Right arrow Articles by Hoban, D. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org
Received June 8, 2006
Revised September 4, 2006
Accepted October 3, 2006

Brief report

Pharmacodynamic activity of ertapenem versus penicillin-susceptible and penicillin-non-susceptible Streptococcus pneumoniae using an in vitro model

George G. Zhanel 1 *, Sheldon Derkatch 2, Nancy Laing 3, Ayman M. Noreddin 4, and Daryl J. Hoban 5

1 Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, 820 Sherbrook Street, Winnipeg, R3A 1R9, Canada; Department of Clinical Microbiology, Health Sciences Centre, Winnipeg, R3A 1R9, Canada; Department of Medicine, Health Sciences Centre, Winnipeg, R3A 1R9, Canada
2 Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, 820 Sherbrook Street, Winnipeg, R3A 1R9, Canada
3 Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, 820 Sherbrook Street, Winnipeg, R3A 1R9, Canada; Department of Medicine, Health Sciences Centre, Winnipeg, R3A 1R9, Canada
4 College of Pharmacy, University of Minnesota, Duluth, MN 55812, USA
5 Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, 820 Sherbrook Street, Winnipeg, R3A 1R9, Canada; Department of Clinical Microbiology, Health Sciences Centre, Winnipeg, R3A 1R9, Canada

* To whom correspondence should be addressed.
George G. Zhanel, E-mail: ggzhanel{at}pcs.mb.ca


  Abstract

Background: Ertapenem is a novel carbapenem with activity against both penicillin-susceptible (MIC ≤ 0.06 mg/L) and penicillin-non-susceptible (MIC ≥ 0.12 mg/L) Streptococcus pneumoniae. This study assessed the pharmacodynamic activity of ertapenem against penicillin-susceptible and penicillin-non-susceptible S. pneumoniae using an in vitro pharmacodynamic model.

Methods: Fifteen S. pneumoniae strains including 3 penicillin-susceptible and 12 penicillin-non-susceptible [4 penicillin-intermediate (MIC 0.12-1 mg/L) and 8 penicillin-resistant (MIC ≥ 2 mg/L); with different resistance phenotypes including erythromycin-resistant (MIC ≥ 1 mg/L), ciprofloxacin-resistant (MIC ≥ 4 mg/L) and doxycycline-resistant (MIC ≥8 mg/L)] were studied. The in vitro pharmacodynamic model was inoculated with 1 x 106 cfu/mL and ertapenem was dosed once daily at 0 and 24 h to simulate f (free) Cmax and t1/2 obtained after a standard 1 g intravenous once daily dose in healthy volunteers (fCmax 15 mg/L, t1/2 4 h). Sampling was performed for 48 h to assess viable growth.

Results: Ertapenem T > MIC ≥ 80% (ertapenem MICs ≤ 0.5 mg/L) resulted in bactericidal (≥3 log10 killing) activity at 12, 24 and 48 h with complete eradication of penicillin-susceptible and penicillin-non-susceptible S. pneumoniae from the model with no regrowth over the 48 h study period. Ertapenem T > MIC ≤ 63% (ertapenem MIC ≥ 1 mg/L) resulted in bactericidal activity at 12 h with regrowth at 24 and 48 h. The observed MICs for S. pneumoniae of ertapenem studied in the in vitro model did not change during the 48 h period, even for strains where regrowth occurred.

Conclusions: Ertapenem is bactericidal against both penicillin-susceptible and penicillin-non-susceptible S. pneumoniae (ertapenem MICs ≤ 0.5 mg/L) when simulating free drug after 1 g intravenous once daily dosing.

Keywords: resistance; pharmacokinetics; antimicrobials.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
G. G. Zhanel, P. Baudry, V. Vashisht, N. Laing, A. M. Noreddin, and D. J. Hoban
Pharmacodynamic activity of ertapenem versus multidrug-resistant genotypically characterized extended-spectrum {beta}-lactamase-producing Escherichia coli using an in vitro model
J. Antimicrob. Chemother., March 1, 2008; 61(3): 643 - 646.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.